Introduction
Zynlonta Car T Treatment, also known as CAR-T cell therapy, is a breakthrough treatment for certain types of cancer. It involves genetically modifying a patient's own immune cells, called T cells, to recognize and destroy cancer cells. This personalized therapy offers new hope for patients who have not responded to traditional treatments.
Step 1: Collection of T Cells
The first step in Zynlonta Car T Treatment is the collection of T cells from the patient's blood. This process, known as leukapheresis, involves removing blood from the patient, separating out the T cells, and returning the remaining blood components back to the patient. The collected T cells are then sent to a laboratory for genetic modification.
Step 2: Genetic Modification
In the laboratory, the collected T cells undergo genetic modification to introduce a chimeric antigen receptor (CAR) gene. This gene encodes a receptor that can recognize a specific antigen on cancer cells. The modified T cells are then expanded in the laboratory to increase their numbers.
Step 3: Conditioning
Before the infusion of the modified T cells, the patient undergoes a conditioning regimen. This typically involves chemotherapy or radiation therapy to eliminate existing cancer cells and create space for the infused CAR-T cells to proliferate. The conditioning also helps to suppress the patient's immune system temporarily.
Step 4: CAR-T Cell Infusion
Once the conditioning is complete, the patient receives the infusion of the genetically modified CAR-T cells. These CAR-T cells can recognize and bind to the specific antigen present on cancer cells, leading to their destruction. The infused CAR-T cells continue to multiply and target cancer cells throughout the body, offering a durable and targeted treatment approach.